mii-exa-medikation-medication-statement-intravenous-use - MII IG Medikation v2027.0.0-ballot

MII IG Medikation
2027.0.0-ballot - Germany

This page is part of the MII Implementation Guide MII IG Medikation (v2027.0.0-ballot: 2027 Ballot 2) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Beispiel MedicationStatement: mii-exa-medikation-medication-statement-intravenous-use

German

Profile: MII PR Medikation MedicationStatement version: 2027.0.0-ballot

Security Label: test health data (Details: ActReason code HTEST = 'test health data')

partOf: Procedure Applikation von Medikamenten, Liste 7: Thiotepa, parenteral: 2.400 mg bis unter 2.600 mg

status: Completed

medication: Medication

subject: Max Mustermann Male, DoB: 1965-03-14 ( https://www.medizininformatik-initiative.de/fhir/core/modul-medikation/sid/patient#12345)

effective: 2018-05-26

dosage
timing: Count 1 times, Once
route: Intravenous use
DoseAndRates
- Dose[x]
* 2400-2600 milligram

IG © 2019+ NUM-DIZ. Package de.medizininformatikinitiative.kerndatensatz.medikation#2027.0.0-ballot basiert auf FHIR 4.0.1. Erstellt 2026-09-11
Links: Inhaltsverzeichnis | QA-Bericht | netzwerk-universitaetsmedizin.de | medizininformatik-initiative.de | Impressum
HL7®, FHIR® and the FHIR flame design are registered trademarks of Health Level Seven International. Their use does not constitute endorsement by HL7.